AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
Contenido no disponible. Consulta la fuente original.
AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.